TranslatePolitics.com

Recent debates

8 latest topics

09-03 Protect Economic and Academic Freedom Act of 2026 13 statements 09-03 Moment of Silence in Honor of the 25th Anniversary of September 11 2 statements 09-03 Honoring Former U.S. Representative Charles Hatcher of Georgia 2 statements 09-03 Recognizing Firefighters from California's Third Congressional District 17 statements 09-02 Saluting White Plains Beautification Foundation 2 statements 09-02 Celebrating Rural Lawyer Julie Bear 4 statements 09-02 Operation Midway Blitz Anniversary 2 statements 09-02 Catherine Watts Celebrates 100th Birthday 4 statements

House of Representatives

FDA Modernization Act 3.0

2026-07-20 Issue 118 Showing 1–4 of 4

Official Congressional Record ↗

Brett Guthrie

Republican

“I don't have anything to work with here. This request only includes the speaker's instructions to the House clerk. It doesn't have an actual statement I can translate yet.”

Brett Guthrie

Republican

“I like this bill. I want the government to say 'nonclinical' instead of 'animal' in its rules. People have concerns about animal testing. Researchers are using new ways to test drugs. I like that. I thank people from Georgia.”

Official Congressional Record

Mr. Speaker, I yield myself such time as I may consume. Mr. Speaker, I rise today in strong support of H.R. 2821, led by my colleagues Representative Carter of Georgia and Representative Barragan, which requires the Secretary of HHS to publish rules amending certain regulations by replacing references to ``animal'' tests, data, studies, models, and research with the broader term ``nonclinical'' tests, data, studies, models, and research. Biomedical research typically utilizes animal models to explore biological processes, analyze diseases, and explore potential therapies. However, given the concerns and scientific limitations of animal testing, researchers have increasingly turned to new approach methodologies to evaluate drugs when scientifically justified. The scientific community has worked diligently to balance animal welfare concerns and the value of animal tests and research. I am pleased with the progress to date and look forward to seeing continued evidence-driven advancements in this space. I commend the administration for their work to phase out animal testing where it is scientifically appropriate and for achieving the key goals in the first year of implementing the roadmap to reducing animal testing in preclinical safety studies. Mr. Speaker, I appreciate my colleague from Georgia for putting this bill forward, and I reserve the balance of my time.

View on ourcommons.ca ↗

Brett Guthrie

Republican 2:50 p.m.

“I want to praise my friend Mr. Carter from Georgia. He helps run the committee that oversees the FDA. He's a leader on this issue. I like him a lot.”

Earl L. "Buddy" Carter

Republican 2:50 p.m.

“I want my bill to pass. It will change FDA rules about animal testing. I want to protect animals. I think the last administration did not do enough. My bill will make it better. We should use new technology instead of testing on animals. My bill will not lower standards, it will raise them. It will help patients too. It will make drug development faster and better. It's a common sense bill that helps animals and people. I think both sides should want this.”

Official Congressional Record

Mr. Speaker, I thank the gentleman for yielding. Mr. Speaker, I rise today in strong support of my bill, H.R. 2821, the FDA Modernization Act 3.0, bipartisan legislation that ensures the FDA fully embraces modern science while reducing unnecessary animal testing. Many of our families would feel incomplete without the pets and animals that bring unconditional love into our lives. Yet every year, millions of animals, including dogs, man's best friend, are still subjected to testing in the development of new medicines. As policymakers, we have a responsibility to protect those who cannot protect themselves. That responsibility includes embracing scientific innovation that can reduce unnecessary animal suffering while continuing to deliver safe and effective treatments to patients. In 2022, Congress took an important first step by passing the FDA Modernization Act 2.0. I was proud to help lead that effort. That law gave drug developers the ability to use modern, scientifically validated alternatives to traditional animal testing when appropriate. Congress made its intent clear. We wanted to encourage more effective, more humane, and more innovative approaches to drug development. Unfortunately, the previous administration failed to fully implement the law. Without clear implementation, too many researchers have lacked the certainty they need, and too many animals continue to be used in testing that modern science can increasingly replace. H.R. 2821 ensures the FDA finally carries out the will of Congress. This bill is not lowering standards. It is about raising them. Today's researchers have access to technologies that simply did not exist a generation ago: advanced human cell models, organ-on-a-chip technology, artificial intelligence, and computational modeling. These innovative tools have the potential to better predict how medicines will perform in humans while reducing reliance on animal testing. Our laws should reflect the science of today, not the science of decades past. Modernizing drug development doesn't just benefit animals. It benefits patients. By providing greater clarity and encouraging the use of validated alternative methods, we can make the drug development process more efficient. That means fewer unnecessary delays and more innovation. Ultimately, that means lifesaving treatments can reach patients more quickly without compromising the FDA's rigorous standards for safety and effectiveness. This is a commonsense, bipartisan bill. It reflects a simple principle: We can advance medical innovation while improving animal welfare. Those goals are not in conflict. In fact, they go hand in hand. Mr. Speaker, the FDA Modernization Act 3.0 fulfills the promise Congress made when we passed the FDA Modernization Act 2.0. It ensures that modern science is fully incorporated into our regulatory process. It helps reduce unnecessary animal testing and strengthens American medical innovation. It also helps bring new therapies to patients more efficiently. I urge my colleagues to support H.R. 2821, the FDA Modernization Act 3.0.

View on ourcommons.ca ↗

What they said. What they meant.

Recent debates